Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: First Affiliated Hospital of Henan University of Science and Technology, Hubei Cancer Hospital, First Affiliated Hospital of Xinxiang Medical University, Henan Medical University, First Affiliated Hospital Zhejiang University, Zhengzhou University, Fudan University, Fudan University Shanghai Cancer Center, Qingdao University, Yuhuangding Hospital, Southwest Medical University, Affiliated Hospital of Southwest Medical University, Hunan Cancer Hospital, Nanjing Drum Tower Hospital, Nanjing University, Huashan Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410814370